QLT Inc. (USA)  

(Public, NASDAQ:QLTI)   Watch this stock  
Find more results for QLTI
3.80
+0.02 (0.53%)
Aug 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.71 - 3.81
52 week 3.22 - 6.68
Open 3.71
Vol / Avg. 0.00/169,094.00
Mkt cap 198.62M
P/E     -
Div/yield     -
EPS -0.11
Shares 52.83M
Beta -0.18
Inst. own 49%
Oct 26, 2015
Q3 2015 QLT Inc Earnings Release (Estimated) Add to calendar
Jul 29, 2015
Q2 2015 QLT Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -27.78% -2.47%
Return on average equity -28.86% -2.55%
Employees 31 -
CDP Score - -

Address

887 Great Northern Way Suite 250
VANCOUVER, BC V5T 4T5
Canada
+1-604-7077000 (Phone)
+1-604-7077001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

QLT Inc. (QLT) is a biotechnology company engaged in the development and commercialization of ocular products. QLT is engaged in the development of QLT091001 for the treatment of Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, a biochemical component of the visual retinoid cycle, and is used for the treatment of certain age-related and inherited retinal degenerative diseases. The Company's QLT091001 product candidate has completed a Phase Ib retreatment study for the treatment of LCA and RP, a Phase Ib study for the treatment of RP with autosomal dominant mutation in retinal pigment epithelium protein 65 (RPE65) and a Phase IIa study for the treatment of impaired dark adaptation (IDA). QLT091001 has received orphan drug designations for the treatment of LCA and RP by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Officers and directors

Jason M. Aryeh Independent Chairman of the Board
Age: 46
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Interim Chief Executive Officer, Director
Age: 71
Bio & Compensation  - Reuters
Glen Ibbott Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
John W. Kozarich Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Jeffrey A. Meckler Independent Director
Age: 48
Bio & Compensation  - Reuters
Stephen L. Sabba M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
John C. Thomas Jr. Independent Director
Age: 61
Bio & Compensation  - Reuters